| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1024688188 |
| P356 | DOI | 10.2165/11595910-000000000-00000 |
| P698 | PubMed publication ID | 22136182 |
| P50 | author | Felipe Ades | Q59158713 |
| P2093 | author name string | Kamal S Saini | |
| Otto Metzger-Filho | |||
| Rodrigo Dienstmann | |||
| P2860 | cites work | Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis | Q24608039 |
| Tumor angiogenesis: therapeutic implications | Q27860595 | ||
| Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer | Q27860681 | ||
| Anti-vascular endothelial growth factor therapy for breast cancer: can we pick the winners? | Q84069421 | ||
| RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic br | Q85077949 | ||
| A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer | Q28183621 | ||
| Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer | Q28278736 | ||
| Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer | Q29614302 | ||
| Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis | Q29614537 | ||
| Integrating bevacizumab, everolimus, and lapatinib into current neoadjuvant chemotherapy regimen for primary breast cancer. Safety results of the GeparQuinto trial | Q33390705 | ||
| Incidence and risk of significantly raised blood pressure in cancer patients treated with bevacizumab: an updated meta-analysis | Q33558693 | ||
| Independent review of E2100: a phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer | Q33561160 | ||
| Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer | Q34022546 | ||
| Disease course patterns after discontinuation of bevacizumab: pooled analysis of randomized phase III trials | Q34625332 | ||
| Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis | Q34626720 | ||
| Rapid vascular regrowth in tumors after reversal of VEGF inhibition | Q35052385 | ||
| A phase II pilot trial incorporating bevacizumab into dose-dense doxorubicin and cyclophosphamide followed by paclitaxel in patients with lymph node positive breast cancer: a trial coordinated by the Eastern Cooperative Oncology Group | Q35693076 | ||
| Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer | Q36024588 | ||
| Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. | Q37121685 | ||
| A feasibility study of bevacizumab plus dose-dense doxorubicin-cyclophosphamide (AC) followed by nanoparticle albumin-bound paclitaxel in early-stage breast cancer | Q37197579 | ||
| Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis | Q37328873 | ||
| Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis | Q37501707 | ||
| Bevacizumab for salvage treatment of metastatic breast cancer: a systemic review and meta-analysis of randomized controlled trials | Q37597935 | ||
| Progression-free survival: gaining on overall survival as a gold standard and accelerating drug development | Q37614173 | ||
| Overall survival: a gold standard in search of a surrogate: the value of progression-free survival and time to progression as end points of drug efficacy | Q37614176 | ||
| Progression-free survival as surrogate and as true end point: insights from the breast and colorectal cancer literature | Q37630084 | ||
| Bevacizumab in metastatic breast cancer: a meta-analysis of randomized controlled trials. | Q37671720 | ||
| Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis of randomized controlled trials | Q37692420 | ||
| Bevacizumab in combination with taxanes for the first-line treatment of metastatic breast cancer. | Q37718401 | ||
| Increased Risk of Serious Hemorrhage with Bevacizumab in Cancer Patients: A Meta-Analysis | Q37807240 | ||
| Bevacizumab/docetaxel association is more efficient than docetaxel alone in reducing breast and prostate cancer cell growth: a new paradigm for understanding the therapeutic effect of combined treatment | Q42930179 | ||
| Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer | Q43111250 | ||
| The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors | Q43579728 | ||
| Congestive heart failure risk in patients with breast cancer treated with bevacizumab. | Q44082273 | ||
| RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer | Q44963911 | ||
| First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2,251 patients. | Q53073357 | ||
| Avastin's commercial march suffers setback | Q54650821 | ||
| Intracranial hemorrhage in patients with cancer treated with bevacizumab: the Memorial Sloan-Kettering experience | Q60492076 | ||
| Bevacizumab increases the risk of arterial ischemia: a large study in cancer patients with a focus on different subgroup outcomes | Q82656539 | ||
| Bevacizumab and breast cancer: the E2100 outlier | Q82711662 | ||
| Addition of bevacizumab to chemotherapy for treatment of solid tumors: similar results but different conclusions | Q82845146 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | bevacizumab | Q413299 |
| P304 | page(s) | 15-25 | |
| P577 | publication date | 2012-01-01 | |
| P1433 | published in | Drug Safety | Q15724462 |
| P1476 | title | Benefit-risk assessment of bevacizumab in the treatment of breast cancer | |
| P478 | volume | 35 |
| Q36248498 | Bevacizumab and Breast Cancer: A Meta-Analysis of First-Line Phase III Studies and a Critical Reappraisal of Available Evidence |
| Q37011741 | Breast cancer as a systemic disease: a view of metastasis |
| Q36751861 | Cardiovascular complications associated with novel angiogenesis inhibitors: emerging evidence and evolving perspectives |
| Q37417880 | Evaluation of a novel macromolecular cascade-polymer contrast medium for dynamic contrast-enhanced MRI monitoring of antiangiogenic bevacizumab therapy in a human melanoma model |
| Q51619428 | Systematic prioritization of cancer combination therapies: are we really on target? |
| Q37274132 | Targeting the tumor microenvironment: from understanding pathways to effective clinical trials |
Search more.